Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Longitudinal Clinical and Neuroanatomical Changes of PD-MCI Reverters
Movement Disorders
P12 - Poster Session 12 (12:00 PM-1:00 PM)
3-005

To investigate baseline and longitudinal clinical and neuroanatomical features of patients with Parkinson’s disease who experienced mild cognitive impairment, but reverted to normal cognition overtime (PD-MCIr) compared to PD with normal cognition (PD-CN), stable MCI (PD-MCIs), and patients who converted to MCI (PD-MCIc) or dementia (PD-Dc).

Longitudinal studies identified a group of PD patients with MCI that reverted to normal cognition overtime.

We recruited 154 patients with known cognitive-outcome after 4 years: 12 PD-MCIr, 55 PD-CN, 37 PD-MCIc, 26 PD-MCIs, and 24 PD-Dc. Patients underwent four visits, including neuropsychological/clinical assessments and MRI scans. Clinical/cognitive features, and regional cortical thickness (CT) progression overtime were investigated within and between groups.
At baseline, compared to PD-MCIc, PD-MCIs and PD-Dc, PD-MCIr patients had younger age, lower treatment dose, shorter disease duration, less motor and non-motor disturbances, and greater CT in the parieto-temporal cortices and subcortical regions. On the other hand, compared to PD-CN, PD-MCIr patients had lower education, performed worse in cognition, and experienced more gastrointestinal symptoms. However, PD-MCIr and PD-CN groups showed similar CT features. Overtime, PD-MCIr patients showed a global worsening of motor and non-motor symptoms, and decreased CT in fronto-temporal regions, in a way similar to that of the PD-CN group, except for lower cognitive performances. At the last visit, compared to PD-MCIc, PD-MCIs and PD-Dc cases, PD-MCIr patients still showed a better motor and non-motor condition, and ticker cortical structures. 
PD-MCIr is associated to a mild phenotype and a relatively preserved brain structure relative to patients with a progressive cognitive decline. The PD-MCIr group remains similar to PD-CN cases overtime, except for a cognitive vulnerability that in this group seems to be independent of the progression of motor and (other) non-motor disturbances. 
Authors/Disclosures

PRESENTER 		No disclosure on file
Federica Agosta (San Raffaele Scientific Institute) Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC.
Elisa Canu (Ospedale San Raffaele) The institution of Elisa Canu has received research support from Italian Ministry of Health .
No disclosure on file
Silvia Basaia Silvia Basaia has nothing to disclose.
Iva Stankovic (Neurology Clinic, Clinical Center of Serbia, University of Belgrade) Iva Stankovic has nothing to disclose.
Alexandra Tomic No disclosure on file
Elka Stefanova No disclosure on file
No disclosure on file
Vladimir S. Kostic, MD, PhD (Institute of Neurology CCS) Dr. Kostic has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Roche. An immediate family member of Dr. Kostic has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Alkaloid. The institution of Dr. Kostic has received research support from Ministry of Â鶹´«Ã½Ó³»­, Science and Technological Development of Serbia.
Massimo Filippi, MD, FÂ鶹´«Ã½Ó³»­ (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.